publication

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN

Xiao, W. et al.
Blood Advances (2020)

Abstract

Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition.
Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.

Authors

Xiao, W., Miles, L.A.., Bowman R.L., Durani, V., Tian H.S., DelGaudio, N.L., Mishra, T., Zhu, M. Zhang, Y., Stump, S.E.., Tallman, M.S., Levine, R.L.., Cai, S.F.

VIEW

publication

Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma

Marin-Bejar, O.

Cancer Cell (2021)

publication

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Thijssen, R.

Blood (2021)

publication

Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis

Dillon, L.W.